Health
Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas – News-Medical.Net
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
Noosa News24 hours ago$20 million program to help women return to work
-
Noosa News24 hours agoSerious traffic crash, Noosa – Sunshine Coast
-
General20 hours agoThousands join pro-Palestinian rallies in towns and cities across Australia amid ceasefire
-
General20 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test